This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I've seen the following sequence of events several times. I can't prove the exact causality, but I have a strong suspicion about what is going on here. You can be the judge. clinical presentation A patient presents for management of a pleural effusion. A pigtail chest drain is inserted without difficulty or complication. The drain […] EMCrit Project by Josh Farkas.
In an instant, more than 1,000 patients at my health care clinic outside Nairobi lost access to lifesaving HIV treatments. Thousands more could no longer receive treatment for tuberculosis or contraception that prevents teenage pregnancies, hurting the well-being of our communities and threatening the progress we’ve made in their medical care.
A U.K. government proposal to raise mandatory rebates that drug companies are required to pay to bolster the National Health Service has sparked criticism from an industry trade group, which argues the move will undermine efforts to make life sciences a key pillar of the economy. At issue is a program called the statutory scheme, which was created several years ago and is one of two initiatives in which the government uses rebates to cap the cost of brand-name medicines for the NHS.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content